DNARx
DNARx is dedicated to transforming gene therapy through innovative, nonviral DNA-based platforms like HEDGES, aiming to provide safe, effective, and versatile treatments for a wide range of diseases including cancer, genetic disorders, and pandemic infections. Their mission is to develop the safest and most effective gene delivery tools to improve patient outcomes worldwide.
Industries
Nr. of Employees
small (1-50)
DNARx
235 Berry Street, #610, San Francisco, CA 94158
Patents
Products
Nonviral DNA-based gene delivery platform
A platform combining DNA constructs and liposome-based carriers designed for systemic delivery, tunable-duration expression, multigene and large-construct expression, and repeat dosing in preclinical models.
Nonviral DNA-based gene delivery platform
A platform combining DNA constructs and liposome-based carriers designed for systemic delivery, tunable-duration expression, multigene and large-construct expression, and repeat dosing in preclinical models.
Services
Design and execution of preclinical programs including DNA vector design, formulation development, systemic and localized delivery, animal efficacy studies, and bioanalytical assessment of expressed products.
Formulation optimization and manufacturing approaches for nonviral DNA-encoded therapeutics with an emphasis on scalable, lower-complexity production compared with viral vectors.
Program development and execution in collaboration with government sponsors to generate DNA-encoded prophylactics and therapeutics for pandemic pathogens.
Design and execution of preclinical programs including DNA vector design, formulation development, systemic and localized delivery, animal efficacy studies, and bioanalytical assessment of expressed products.
Formulation optimization and manufacturing approaches for nonviral DNA-encoded therapeutics with an emphasis on scalable, lower-complexity production compared with viral vectors.
Program development and execution in collaboration with government sponsors to generate DNA-encoded prophylactics and therapeutics for pandemic pathogens.
Expertise Areas
- Nonviral gene delivery
- Multigene and large-construct expression
- Formulation-driven expression control
- Preclinical in vivo development and efficacy testing
Key Technologies
- Nonviral DNA delivery
- Liposome-based carrier systems
- Enhancer-promoter vector design
- Large-capacity DNA construct engineering
News & Updates
DNARx’s proprietary HEDGES™ non-viral gene therapy delivery platform promises rapid, reliable, low-cost and relatively simple manufacturing and delivery of gene vectors to treat a wide range of diseases, particularly as compared to currently-employed delivery of genes using viruses.
The outbreak of the coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has infected more than 100,000 people worldwide with over 3,000 deaths since December 2019. There is no cure for COVID-19 and the vaccine development is estimated to require 12-18 months.
Alzheimer’s disease (AD) is the most common form of dementia and has affected millions of individuals worldwide. The hallmarks of AD include the amyloid beta plaque deposits, tau neurofibrillary tangles, altered neuronal signaling, alongside decline in memory…
Sickle cell anemia (SCA) is a hereditary blood disease caused by a single-gene mutation that affects millions of individuals world-wide. In this review, we focus on techniques to treat SCA by ex vivo genetic manipulation of hematopoietic stem/progenitor cells (HSPCs)…
DNARx’s proprietary HEDGES™ non-viral gene therapy delivery platform promises rapid, reliable, low-cost and relatively simple manufacturing and delivery of gene vectors to treat a wide range of diseases, particularly as compared to currently-employed delivery of genes using viruses.
The outbreak of the coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has infected more than 100,000 people worldwide with over 3,000 deaths since December 2019. There is no cure for COVID-19 and the vaccine development is estimated to require 12-18 months.
Alzheimer’s disease (AD) is the most common form of dementia and has affected millions of individuals worldwide. The hallmarks of AD include the amyloid beta plaque deposits, tau neurofibrillary tangles, altered neuronal signaling, alongside decline in memory…
Sickle cell anemia (SCA) is a hereditary blood disease caused by a single-gene mutation that affects millions of individuals world-wide. In this review, we focus on techniques to treat SCA by ex vivo genetic manipulation of hematopoietic stem/progenitor cells (HSPCs)…